Product Information
IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $2.9484 per EA under NDC 00378224693. Its NADAC has been published 451 times since Nov 8, 2017.
Strength
400 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378224693
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA204644On Market Since
9/28/2017
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 451 times since Nov 8, 2017, and over the history we have for it it has declined 97.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.9484 per EA |
|---|---|
| All-time high | $123.6453 (Jan 10, 2018) |
| All-time low | $1.4080 (Aug 23, 2023) |
| 52-week high | $3.2150 |
| 52-week low | $2.6631 |
| Median price | $3.2150 |
| Average price | $12.6137 |
| Largest weekly change | +100.9% (Mar 18, 2020) |
| Weeks tracked | 451 |
| Tracking since | Nov 8, 2017 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $2.9484 per EA (NDC 00378224693), effective Jun 24, 2026.
How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 97.6%. It has been tracked across 451 weekly CMS publications since Nov 8, 2017.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?
Since Nov 8, 2017, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $123.6453 (Jan 10, 2018), with a median of $3.2150 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as IMATINIB MESYLATE 400 MG TAB, but none are currently priced below it.
Who manufactures IMATINIB MESYLATE 400 MG TAB?
IMATINIB MESYLATE 400 MG TAB (NDC 00378224693) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification